| Category | Hyaluronic Skincare |
| Founded | 2012 |
| Headquarters | Beijing / Jinan |
| Listing | Listed via parent Bloomage · 688363.SH (STAR Market, Nov 2019) |
| Latest revenue | Parent Bloomage FY2025 revenue RMB 4.20bn, net profit RMB 291m |
| Hero SKUs | White Bandage Ampoule / Hydra Ampoule |
Brand History
Launched by Bloomage in 2012, Biohyalux extended the group's position as a major sodium hyaluronate supplier into consumer products. The single-use ampoule format solved a real problem — hyaluronic acid is prone to contamination and loses potency after opening — and by 2018 the format was spreading through clinics and social platforms.
The 2020-2022 peak saw Bloomage's functional skincare segment exceed RMB 4.6bn. Competition then intensified: recombinant collagen took over the ingredient narrative, the ampoule format was widely copied, and deliberate cuts to inefficient marketing pushed the segment down. Bloomage's 2025 revenue was RMB 4.20bn with skincare at RMB 1.49bn (-42.1%); the group now leans on synthetic biology while Biohyalux iterates its classics and expands into clinics and offline.
Hero Products
Three-Year Financials
| Year | Revenue (RMB bn) | YoY | Net profit (RMB bn) |
|---|---|---|---|
| 2023 | 60.76 | -4.45% | 5.93 |
| 2024 | 53.71 | -11.6% | 1.74 |
| 2025 | 41.99 | -21.82% | 2.91 |
Brand-level：Biohyalux is not reported separately. Bloomage's skin-science conversion business, mainly functional skincare, fell 42.1% to RMB 1.49bn in 2025 — about 35% of group revenue.
Source：Bloomage annual reports 2023-2025
Company Coverage
- 2026-04Bloomage FY2025: RMB 4.20bn revenue, skincare under pressure
Functional skincare fell 42.1%; the group will cut inefficient marketing and focus on ingredients, aesthetics and synthetic biology.
Source：Annual report - 2025-11Ampoule category enters stock competition
Copycats diluted price bands and efficacy claims.
Source：Trade media - 2025-07New ingredients from the synthetic-biology platform
An attempt to rebuild authority around a new ingredient narrative.
Source：Company filings